- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THARIMMUNE Aktie jetzt für 0€ handeln | |||||
| 17.10. | Tharimmune files to sell 0.326M shares of common stock for holders | 1 | Seeking Alpha | ||
| 17.10. | Tharimmune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.10. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Tharimmune erhöht Gehälter für Führungskräfte und passt Klauseln für Kontrollwechsel an | 3 | Investing.com Deutsch | ||
| 05.09. | Tharimmune erfüllt nach Kapitalmaßnahmen wieder die Nasdaq-Notierungsanforderungen | 2 | Investing.com Deutsch | ||
| 05.09. | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.08. | Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale | 3 | Insider Monkey | ||
| 26.08. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Stocks Moving Premarket: Aethlon Medical, Tharimmune, Brazil Potash And Other Gainers & Losers | 351 | AFX News | OTTAWA (dpa-AFX) - At 7:32 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.08. | Tharimmune Rockets 42% After Hours - Adding To Stunning 206% Daytime Rally: What's Going On? | 11 | Benzinga.com | ||
| 20.08. | Tharimmune Stock Nearly Doubles To 104% On Positive Simulation Results For TH104 | 18 | RTTNews | ||
| 20.08. | Tharimmune meldet positive Ergebnisse für Opioid-Gegenmittel TH104 | 21 | Investing.com Deutsch | ||
| 20.08. | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | 378 | ACCESS Newswire | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| 14.08. | Tharimmune, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Tharimmune expands IP portfolio for opioid countermeasure technology | 3 | Investing.com | ||
| 13.08. | Tharimmune Inc.: Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl | 353 | ACCESS Newswire | RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| 07.08. | Tharimmune, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.08. | Tharimmune Inc.: Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors | 271 | ACCESS Newswire | RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| 04.08. | Tharimmune Inc.: Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery | 253 | ACCESS Newswire | -Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl-TH023 may fulfill the promise of delivering... ► Artikel lesen | |
| 28.07. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,25 | -1,60 % | BioNTech will CureVac - der nächste Schritt | Seit Mitte Juni ist es amtlich: BioNTech will sich den ebenfalls in Deutschland beheimateten Wettbewerber CureVac unter den Nagel reißen. Nachdem das Bundeskartellamt grünes Licht für den Zusammenschluss... ► Artikel lesen | |
| CUREVAC | 4,602 | +0,09 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 253,10 | +1,08 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| NOVAVAX | 7,201 | -1,42 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 127,95 | -0,31 % | Biogen Inc.: Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease | TOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| MAINZ BIOMED | 1,470 | -6,96 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,325 | +1,59 % | Viking Therapeutics-Aktie: Die spannendste Adipositas-Wette? | Nach unserem letzten Kauftipp Ende vergangenen Monats hat die Aktie von Viking Therapeutics wieder Fahrt aufgenommen und konnte über 20% zulegen. Vor den kommenden Quartalszahlen kocht die Spannung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,878 | -25,68 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 77,00 | +3,36 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| BIOCRYST PHARMACEUTICALS | 6,274 | +0,77 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | ||
| BIOMARIN PHARMACEUTICAL | 44,990 | -2,05 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 20,190 | -2,65 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen | |
| EXELIXIS | 34,280 | -0,32 % | Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,668 | -2,33 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| CARDIOL THERAPEUTICS | 1,014 | +0,60 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
23.10.2025 / 12:51 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
THARIMMUNE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,080 (+2,74 %) liegt der Kurs bei 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THARIMMUNE INC finden Sie auf Wallstreet Online.